MedTech leadership
-
When Better Teams Make Slower Decisions
Leadership in Flow | Harun Rabbani, Precilium Last year, the regulatory submission went out late. Not because the science was weak. Not because the team lacked experience. But because three people believed they had authority over the final sign-off, and by the time that ambiguity was resolved, the window had narrowed. This year, the same…
-
Why Most Scale-Stage Problems Are Misdiagnosed
The most important problems inside scale-stage MedTech organisations are often misdiagnosed. What appears to be a hiring issue, communication breakdown or operational slowdown may actually be a sign that organisational complexity has begun outpacing leadership architecture. Recent developments involving Ennov, xWave Technologies and ŌURA illustrate this particularly clearly. These are often presented as growth stories,…
-
The Moment Optionality Begins to Narrow in MedTech Scale-Ups
If you have not yet watched this week’s Signal Before Scale episode on Olive AI and invisible momentum collapse in MedTech, I would strongly encourage you to begin there. The video explores a strange phenomenon increasingly visible across healthcare technology: How organisations can appear externally successful while internally becoming progressively heavier, slower, and more fragile.…
-
The Hidden Variable Inside MedTech Scale-Ups Right Now
In the previous article, I wrote about the moment optionality begins to narrow in MedTech scale-ups. The natural question for boards is what determines whether that shift is recognised early, or only noticed once timelines begin to stretch. Across portfolios, the answer is rarely capital, rarely technology, and it is almost never effort. The hidden…
-
The Moment Optionality Begins to Narrow in MedTech Scale-Ups
A MedTech company can feel as though it is moving closer to market, while at the same time moving closer to only one version of its market. That difference is easy to miss. Early in a scale-up journey, optionality feels almost unlimited. Multiple regulatory paths look possible. Several clinical strategies appear sensible. Different positioning stories…
-
When Regulatory Conversations Quietly Rewrite the Strategy
Most MedTech strategies are not rewritten in board meetings. They are rewritten gradually, often almost invisibly, through conversations with regulators that at the time appear to be clarifications rather than decisions. This is not because regulators intend to shape company direction. It happens because evidence-based environments reveal reality step-by-step, and each clarification alters what the…
-
When Progress Quietly Reduces Your Options
Progress feels a little like driving on a motorway. When the road is clear and the car is moving quickly, it is natural to assume you have plenty of options. After all, you are travelling faster and covering more ground than before. But there is a small paradox in motorway driving that anyone who has…
-
Why Boards Often Realise the Value of a CMO Too Late
Clinical leadership in MedTech is rarely treated as a strategic variable at the start. In early stages, it often appears procedural. A role associated with compliance, trials, and regulatory navigation. Certainly treated as important but not always central to valuation. That perception tends to change when the inevitable pressure mounts. As scale approaches, clinical judgement…
-
The Leadership Gap MedTech Will Feel Before It Can Measure
In the coming years, many MedTech organisations will experience delays, friction, and regulatory setbacks that do not feel like failures. They will feel like bad luck. A certification that takes longer than expected. A product that stalls late in development. A launch window that quietly slips. In most cases, the root cause will not be…
ai, artificial-intelligence, business, CTO, How boards assess technical leadership, How MedTech leadership decisions affect regulation, leadership, Leadership risk in regulated healthcare, Leadership Strategy, management, MedTech, MedTech board advisory, MedTech CMO recruitment, MedTech CTO recruitment, MedTech executive hiring, MedTech leadership, MedTech leadership risk, Regulated MedTech leadership, Senior technical leadership MedTech, Tech Leadership, technology, Why MedTech hiring fails at senior level, Why MedTech launches get delayed